Introduction {#S1}
============

Infectious agents are important contributors to the global cancer burden particularly in Africa. Of the 12.7 million new cancer cases that were diagnosed worldwide in 2008, about two million (16.1%) were attributable to infectious agents, of which 1.6 million occurred in less developed regions of the world ([@B1]). In its 2009 review of the carcinogenicity of infectious agents, the International Agency for Research on Cancer (IARC) found sufficient evidence to conclude that seven viruses: human papillomavirus (HPV), Epstein--Barr virus, hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus type-1 (HIV-1), Kaposi's sarcoma herpes virus (KSHV), and human T-cell leukemia virus type-1 (HTLV-1), the bacterium *Helicobacter pylori*, and the parasites *Clonorchis sinensis (C. sinensis), Opisthorchis viverrini (C. sinensis)*, and *Schistosoma haematobium* (*S. haematobium)* were carcinogenic to humans ([@B2]).

The proportion of cancers attributable to infections in developing countries has been estimated to vary between 20 and 30% which contrasts with 3--10% in developed countries ([@B1], [@B3]--[@B5]). Although there are estimates of the burden of infection-associated cancers based on cancer registry data for countries, such as Australia ([@B3]), United Kingdom ([@B4]), Netherlands ([@B5]), United States ([@B6]), South Korea ([@B7]), France ([@B8]), and China ([@B9]), there are no country-specific estimates for countries in Africa, including Nigeria. It is important to quantify the proportion of the cancer burden that could be prevented by the implementation of effective interventions that limit exposure to the infections-associated with cancers, particularly in Africa.

Since the resuscitation and strengthening of cancer registration in Nigeria starting 2009, more population-based cancer registries (PBCRs) have become operational ([@B10]--[@B12]). The aim of this study is to estimate the burden of cancers attributable to infections in Nigeria between 2012 and 2014 from these PBCRs.

Materials and Methods {#S2}
=====================

Data Sources {#S2-1}
------------

We retrieved cancer incidence information from two PBCRs in Nigeria, the Abuja and Enugu cancer registries, for the period 2012--2014. The Abuja Cancer Registry (ABCR), established in 2009, has a catchment area that covers the entire federal capital territory and a population of 1,406,239 people ([@B10]). The Enugu Cancer Registry (ECR) was established in 2012 and covers an area around the greater Enugu city metropolis with a population of 1,103,153 people ([@B12]). The registries utilize the International Classification of Disease for Oncology, 3rd Edition (ICD-O3) for coding and classification of cancers. The ABCR uses CanReg4 software for storing and processing data, while the ECR uses CanReg5. Approval for cancer registration activities and research was obtained from the National Health and Research Ethics Committee of Nigeria (NHREC). Anonymity and confidentiality were maintained in all analyses and publications derived from the cancer registry data.

Data Handling and Statistical Analysis {#S2-2}
--------------------------------------

Data checks were done by Michael Kolawole Odutola and Elima E. Jedy-Agba using the IARC CanReg5 software. We performed quality control checks to remove duplicates, and to ensure logical correctness and overall accuracy of the data. Analysis of incident cancer cases and age standardized incidence rate (ASR) calculation was generated by the CanReg5 software.

For this analysis, we retrieved age and sex-specific number of incident cancers reported by the cancer registries during the period under study. Using the classification of carcinogens by IARC in monograph 100b, we identified the following cancers considered to be associated with infectious agents in humans: nasopharygeal (C11), oropharyngeal (C01, C09, C10), stomach (C16), liver (C22), bladder (C67), Hodgkin lymphoma (HL; C81), non-Hodgkin lymphoma (NHL; C82--C85; C96), Kaposi Sarcoma (KS) (C46), and anal cancers (C21) in both sexes; cervical (C53), vulvar (C51), and vaginal cancers (C52) in females; and penile cancer (C60) in males (Table [1](#T1){ref-type="table"}). We considered all the infectious agents identified by IARC as Group 1 carcinogens, except Human T-cell leukemia virus type-1 (HTLV-1); *C. sinensis* and *O. viverrini* associated with acute T-cell leukemia/lymphoma and cancer of the bile duct, respectively, because of the rarity of these cancers in African populations ([@B13]).

###### 

**List of group 1 carcinogenic biological agents and related cancers**.

  Infections-associated cancers   Group 1 agents
  ------------------------------- ---------------------------------------------------------
  Cervix                          Human papillomavirus
  Vulva                           Human papillomavirus
  Vagina                          Human papillomavirus
  Anus                            Human papillomavirus
  Oropharynx                      Human papillomavirus
  Bladder                         *Schistosoma haematobium*
  Liver                           Hepatitis B virus/hepatitis C virus
  Nasopharynx                     Epstein--Barr virus
  Stomach                         *Helicobacter pylori*
  Non-Hodgkin lymphoma            Epstein--Barr virus/human immunodeficiency virus type-1
  Hodgkin lymphoma                Epstein--Barr virus
  Kaposi sarcoma                  Human herpesvirus 8/human immunodeficiency virus type-1
  Penis                           Human papillomavirus

We used the standard formula for population-attributable fraction (PAF) ([@B4]): $$\text{PAF} = p(r - 1)/\lbrack p(r - 1) + 1\rbrack$$ where *r* represents the relative risk of exposure and *p* its prevalence in the population. The application of this formula requires information about the prevalence of the exposure to the infectious agents in the population, as well as the corresponding relative risks. In previous studies, this method was used to estimate the number of cancers attributable to HBV, HCV, *H. pylori*, and HIV. For HPV and EBV, the PAF was assumed to be equivalent to the prevalence of viral DNA in the tumor cells.

In this study, we used the PAF for infectious agents associated with cancers that are derived from prevalence and risk estimates from developing countries (Table [2](#T2){ref-type="table"}). We did not have PAF from Nigeria because of the absence of rigorous and robust measures of relative risk for the different infectious agents in this population. Additionally, data on prevalence of exposure to most of the infectious agents is scanty. The few prevalence studies from Nigeria had relatively small sample sizes (less than 50) and were not population based. For each infectious agent, we estimated the number of new cancer cases attributable to that infection by multiplying the overall numbers of cancer cases reported per cancer site with the PAF estimates extracted from meta-analyses.

###### 

**Previous prevalence studies on infectious agents and cancer**.

  Infectious agent   Cancer site          ICD-O code      Prevalence of infectious agents in cancers (SSA population) (%)   Studies in African populations                   PAF estimates used in this study %
  ------------------ -------------------- --------------- ----------------------------------------------------------------- ------------------------------------------------ ------------------------------------
  HPV                Cervix               C53             83--98                                                            Nigeria, South-Africa ([@B14]), Ghana ([@B15])   100 ([@B16])
  Vulva              C51                  100             Botswana ([@B17])                                                 40 ([@B18])                                      
  Vagina             C52                  --              None                                                              40--70 ([@B13], [@B18])                          
  Anus               C21                  88              Nigeria, Mali, Senegal ([@B19])                                   88--90 ([@B13], [@B19])                          
  Oropharynx         C01--C02; C09--C10   19              Ghana ([@B20])                                                    12--46 ([@B13], [@B21])                          
  Penis              C60                  68              Kenya ([@B22])                                                    40--48 ([@B13], [@B23])                          
  Shistosoma         Bladder              C67             --                                                                None                                             56 ([@B13])
  HBV/HCV            Liver                C22             74--77                                                            Nigeria ([@B24]), Gambia ([@B25])                92 ([@B13])
  *H. pylori*        Stomach              C16             56--86                                                            Nigeria ([@B26]), Uganda ([@B27])                74 ([@B13])
  EBV                Nasopharynx          C11             --                                                                None                                             100 ([@B13], [@B28])
  HL                 C81                  55              Nigeria ([@B29])                                                  80 ([@B13])                                      
  EBV/HIV            NHL                  C82--C85; C96   80--95                                                            Nigeria ([@B29]), Uganda ([@B30])                100 ([@B13])
  HIV/HHV8           KS                   C46             83                                                                Nigeria, Benin, Côte d'Ivoire, Togo ([@B31])     100 ([@B32], [@B33])

In determining PAF estimates for cervical cancer, we identified other studies from Africa that reported the prevalence of HPV in cervical tumor cells to be between 83 and 98% ([@B14], [@B15]). However, we used a PAF of 100% because it is established that HPV is a necessary cause of cervical cancer ([@B16], [@B34]). For vulvar cancer, we found a Botswanan study with a sample size of 35 which reported an HPV prevalence of 100% ([@B17]). However, we used a PAF estimate of 40% obtained from meta-analyses for developing countries, because of the small sample size used in that study ([@B13]). We did not find any African regional study on the prevalence of HPV in vaginal cancer, hence, we used a PAF estimate of 40--70% from meta-analyses of studies from developing countries ([@B13], [@B18]). Because we did not find any individual study on HPV prevalence in anal cancer from Africa, we used a PAF estimate of 88--90% from meta-analyses that included cases from developing countries, including Nigeria, Mali, and Senegal ([@B13], [@B19]). A study from Ghana showed HPV prevalence of 16% in etiology of oropharyngeal cancer (OPC) ([@B20]), while a study evaluating HPV prevalence in oropharyngeal, and other head and neck cancers in Nigeria had suboptimal sample size and poor tissue sample quality ([@B35]); hence, we used PAF estimate of 12--46% from meta-analyses of studies from developing countries ([@B13], [@B21]). The prevalence of HPV in 22 penile cancer cases from Kenya was found to be 68.2% ([@B22]). As a result of the small sample size, we used a worldwide estimated PAF of 40--48% from meta-analyses ([@B13], [@B23]).

We used a PAF estimate of 56% for bladder cancer associated with *S. haematobium* from a meta-analysis for West-African countries ([@B13]). Although, we identified two studies from Nigeria and Gambia that reported the prevalence of HBV and HCV in liver cancer to range from 74 to 77% ([@B24], [@B25]), we used a PAF estimate of 92% from a meta-analysis of studies from developing countries ([@B13]). Two studies from Nigeria and Uganda evaluated the prevalence of *H. pylori* in stomach cancer to be 72--87% ([@B26], [@B27]); however, we used an estimated PAF of 74% from a meta-analysis of studies from developing countries ([@B13]). We did not find any studies of the prevalence of EBV in nasopharyngeal cancer in SSA, we used a PAF estimate of 100% from a meta-analysis of studies from developing countries ([@B13], [@B28]). For NHL in HIV infections, although we identified two studies from Nigeria and Uganda with prevalence ranging from 80 to 95% ([@B29], [@B30]), we used an estimated PAF of 100% based on meta-analysis of studies from developing countries because of the limited sample size of 44 used in the Nigerian study ([@B13]). The prevalence of EBV infection in Hodgkin's Lymphoma from a Nigerian study was 55% ([@B29]) but the small sample size (11) was small so we used estimated PAF of 80% derived from a meta-analysis of studies from developing countries ([@B13]). HHV8 is recognized as a necessary cause of KS in HIV infections; therefore, we used PAF of 100% for KS ([@B31]--[@B33]).

We carried out sensitivity analyses for cancers attributable to infections, using GLOBOCAN 2012 database for Nigeria. GLOBOCAN 2012 database contains incidence estimates for only 7 (cancer of the liver, cervix, nasopharynx, bladder; HL, NHL; and KS) out of the 12 infections-associated cancers that we evaluated in our analyses.

Results {#S3}
=======

Overview {#S3-1}
--------

Over a 3-year period from 2012 to 2014, the Abuja and Enugu PBCRs reported 4,336 cancer cases \[1,627 (37.5%) in males, 2,709 (62.5%) in females\]. In total, 1,030 (23.8%) cancer cases were associated with infections (Table [3](#T3){ref-type="table"}). The ASR of infections-associated cancers was 44.4 per 100,000. Approximately 90% (328 of 365) and 94% (623 of 665) of these infections-associated cancers were attributable to infections in males and females, respectively (Table [4](#T4){ref-type="table"}). Of all the infections-associated cancers reported, 22.0% (951 of 4,336) were attributable to infections. The ASR for infections-attributable cancers was 41.6 per 100,000. Cancers attributable to infections constituted 20.2% (328 of 1,627) of cases in males and 23.0% (623 of 2,709) in females (Table [4](#T4){ref-type="table"}).

###### 

**Total number of cancer cases associated with infections in Nigeria from 2012 to 2014**.

  Sex           Cancer site          ICD-O code   No. of cancer cases   \% of total cancer   ASR
  ------------- -------------------- ------------ --------------------- -------------------- ------
  Female        Cervix               C53          392                   30.0                 28.3
  Vulva         C51                  25           1.8                   1.3                  
  Vagina        C52                  8            0.6                   0.4                  
  Anus          C21                  17           1.3                   0.7                  
  Oropharynx    C01--C02; C09--C10   8            0.6                   0.5                  
  Bladder       C67                  14           1.1                   1.1                  
  Liver         C22                  52           3.9                   2.7                  
  Nasopharynx   C11                  34           2.5                   1.5                  
  Stomach       C16                  23           1.7                   1.4                  
  NHL           C82--C85; C96        49           3.7                   2.3                  
  HL            C81                  17           1.2                   0.5                  
  KS            C46                  26           2.0                   1.1                  
  Male          Penis                C60          2                     0.2                  0.1
  Anus          C21                  21           2.7                   1.4                  
  Oropharynx    C01--C02; C09--C10   15           1.9                   0.8                  
  Bladder       C67                  30           3.8                   1.4                  
  Liver         C22                  93           11.9                  4.0                  
  Nasopharynx   C11                  47           6.1                   1.7                  
  Stomach       C16                  33           4.4                   1.7                  
  NHL           C82--C85; C96        61           7.6                   2.7                  
  HL            C81                  28           8.7                   1.0                  
  KS            C46                  35           4.6                   1.3                  
  Total                                           1,030                 23.8                 44.4

###### 

**Population-attributable fraction (PAF) and estimated numbers of cancers attributable to infectious agents in Nigeria from 2012 to 2014**.

  Infectious agent                         Cancer site          ICD-O3 code     No. of cancer cases   ASR           PAF %        Cancer cases attributable to infections   ASR
  ---------------------------------------- -------------------- --------------- --------------------- ------------- ------------ ----------------------------------------- ------
  **Female**                                                                                                                                                               
  HPV                                      Cervix               C53             392                   28.3          100          392                                       28.3
  Vulva                                    C51                  25              1.3                   40            10           0.5                                       
  Vagina                                   C52                  8               0.4                   40--70        3--6         0.2--0.3                                  
  Anus                                     C21                  17              0.7                   88--90        15           0.6                                       
  Oropharynx                               C01--C02; C09--C10   8               0.5                   12--46        1--4         0--0.3                                    
  HBV/HCV                                  Liver                C22             52                    2.7           92           48                                        2.5
  EBV                                      Nasopharynx          C11             34                    1.5           100          34                                        1.5
  HL                                       C81                  17              0.5                   80            14           0.4                                       
  EBV/HIV                                  NHL                  C82--C85; C96   49                    2.3           100          49                                        2.3
  HIV/HHV8                                 KS                   C46             26                    1.1           100          26                                        1.1
  *H. pylori*                              Stomach              C16             23                    1.4           74           17                                        1.0
  Schistosoma                              Bladder              C67             14                    1.1           57           8                                         0.6
  Total (% of female cancers)              665 (25.0%)          41.8                                  623 (23.0%)   39.0--39.4                                             
  **Male**                                                                                                                                                                 
  HPV                                      Penis                C60             2                     0.1           40--48       1                                         0.1
  Anus                                     C21                  21              1.4                   88            18           1.2                                       
  Oropharynx                               C01--C02; C09--C10   15              0.8                   12            2--7         0.1--0.4                                  
  HBV/HCV                                  Liver                C22             93                    4.0           92           86                                        3.7
  EBV                                      Nasopharynx          C11             47                    1.7           100          47                                        1.7
  HL                                       C81                  28              1.8                   80            22           1.4                                       
  EBV/HIV                                  NHL                  C82--C85; C96   61                    2.7           100          61                                        2.7
  HIV/HHV8                                 KS                   C46             35                    1.3           100          35                                        1.3
  *H. pylori*                              Stomach              C16             33                    1.7           74           24                                        1.2
  Schistosoma                              Bladder              C67             30                    1.4           57           17                                        0.8
  Total (% of male cancers)                365 (22.4%)          16.9                                  328 (20.2%)   14.2--14.5                                             
  **Total (% of cancers in both sexes)**   1,030 (23.8%)        44.4                                  951 (22.0%)   41.2--41.6                                             

In 2012, GLOBOCAN estimated that 102,079 \[64,709 (63.3%) in women, 37,370 (36.6%) in men\] cancer cases occurred in Nigeria. In total, 35.9% were associated with infections. The ASR for infections-associated cancers in Nigeria from the GLOBOCAN 2012 database was 50.0 per 100,000. Of all the infections-associated cancers reported, 33.8% were attributable to infections. The ASR for infections-attributable cancers in GLOBOCAN 2012 was 47.4 per 100,000 (Table [5](#T5){ref-type="table"}).

###### 

**Sensitivity analyses of cancers attributable to infectious agents in Nigeria from GLOBOCAN 2012 database**.

  Infectious agent                         Cancer site          ICD-O3 code     No. of cancer cases   ASR              PAF %   Cancer cases attributable to infections   ASR
  ---------------------------------------- -------------------- --------------- --------------------- ---------------- ------- ----------------------------------------- ------
  **Female**                                                                                                                                                             
  HPV                                      Cervix               C53             14,089                29.0             100     14,089                                    29.0
  Vulva                                    C51                  NA              NA                    NA               NA      NA                                        
  Vagina                                   C52                  NA              NA                    NA               NA      NA                                        
  Anus                                     C21                  NA              NA                    NA               NA      NA                                        
  Oropharynx                               C01--C02; C09--C10   NA              NA                    NA               NA      NA                                        
  HBV/HCV                                  Liver                C22             4,172                 8.1              92      3,838                                     7.5
  EBV                                      Nasopharynx          C11             406                   0.6              100     406                                       0.6
  HL                                       C81                  345             0.5                   80               276     0.4                                       
  EBV/HIV                                  NHL                  C82--C85; C96   1,778                 2.8              100     1,778                                     2.8
  HIV/HHV8                                 KS                   C46             635                   0.8              100     635                                       0.8
  *H. pylori*                              Stomach              C16             1,014                 2.0              74      750                                       1.5
  Schistosoma                              Bladder              C67             523                   0.7              57      298                                       0.4
  Total (% of female cancers)              22,962 (35.5%)       44.5                                  22,084 (34.1%)   43.0                                              
  **Male**                                                                                                                                                               
  HPV                                      Penis                C60             NA                    NA               NA      NA                                        NA
  Anus                                     C21                  NA              NA                    NA               NA      NA                                        
  Oropharynx                               C01--C02; C09--C10   NA              NA                    NA               NA      NA                                        
  HBV/HCV                                  Liver                C22             7,875                 15.0             92      7,245                                     13.8
  EBV                                      Nasopharynx          C11             656                   1.1              100     656                                       1.1
  HL                                       C81                  559             0.8                   80               447     0.6                                       
  EBV/HIV                                  NHL                  C82--C85; C96   2,328                 3.7              100     2,328                                     3.7
  HIV/HHV8                                 KS                   C46             812                   1.3              100     812                                       1.3
  *H. pylori*                              Stomach              C16             875                   2.0              74      648                                       1.5
  Schistosoma                              Bladder              C67             574                   1.3              57      327                                       0.7
  Total (% of male cancers)                13,679 (36.6%)       25.2                                  12,463 (33.4%)   22.7                                              
  **Total (% of cancers in both sexes)**   36,641 (35.9%)       50.0                                  34,547 (33.8%)   47.4                                              

*NA means data not available*.

Cervical Cancer and HPV {#S3-2}
-----------------------

Cervical cancer was the commonest infections-associated cancer reported by ABCR and ECR within the study period. A total of 392 cases were reported, representing 30% of all cancers in females (Table [3](#T3){ref-type="table"}). The ASR for cervical cancer was 28.3 per 100,000 (Table [3](#T3){ref-type="table"}). The highest numbers of cervical cancer cases were seen in the 45 to 54 years age groups (110 cases), and ages 65 years and above (98 cases). Using a PAF of 100% for cervical cancer cases, we conclude that all 392 cervical cancer cases reported within the study period were attributable to HPV infection, with attributable ASR of 28.3 per 100,000 (Table [4](#T4){ref-type="table"}).

Vulvar Cancer and HPV {#S3-3}
---------------------

There were 25 vulvar cancer cases reported by the PBCRs from 2012 to 2014 representing 1.8% of all female cancers and an ASR of 1.3 per 100,000 (Table [3](#T3){ref-type="table"}). About half of the vulvar cancer cases were seen in the 45 to 54 years age group. Using PAF of 40% from a meta-analysis ([@B18]), 10 of the 25 cases were attributable to HPV infection yielding an attributable ASR of 0.5 per 100,000 (Table [4](#T4){ref-type="table"}).

Vaginal Cancer and HPV {#S3-4}
----------------------

Eight vaginal cancer cases were reported by both registries, constituting 0.6% of female cancers in the study period with an ASR of 0.4 per 100,000 (Table [3](#T3){ref-type="table"}). Three to six of the eight vaginal cancer cases were attributable to HPV infection, using a PAF of 40--70% ([@B13], [@B18]). The ASR for vaginal cancers attributable to HPV infection ranged from 0.2 to 0.3 per 100,000 (Table [4](#T4){ref-type="table"}).

Anal Cancer and HPV {#S3-5}
-------------------

There were 38 anal cancer cases reported by the ABCR and ECR from 2012 to 2014. Seventeen cases were reported in females, representing 1.3% of female cancers and 21 cases reported in males, accounting for 2.7% of male cancers (Table [3](#T3){ref-type="table"}). The combined ASR was 1.1 per 100,000 with ASR of 0.7 per 100,000 for females and 1.4 per 100,000 for males (Table [3](#T3){ref-type="table"}). In our study, anal cancer was the most common HPV-associated cancer in males. Most of the anal cancer cases were seen between the age groups 35 and 54 years (19 cases) in both sexes. Using a PAF of 88 to 90% ([@B13], [@B19]), we estimated that 33 anal cancers in both sexes were attributable to HPV. The combined ASR for anal cancers attributable to HPV infection was 0.9 per 100,000; 1.2 per 100,000 in males and 0.6 per 100,000 in females (Table [4](#T4){ref-type="table"}).

Oropharyngeal Cancer and HPV {#S3-6}
----------------------------

Some 23 oropharyngeal cancer (OPC) were reported by the registries from 2012 to 2014 with 8 cases in males, representing 1.9% of male cancers and 15 cases in females, constituting 0.6% of female cancers (Table [3](#T3){ref-type="table"}). The combined ASR for OPC was 0.7 per 100,000, with 0.8 per 100,000 in males, and 0.5 per 100,000 females, respectively (Table [3](#T3){ref-type="table"}). Using a PAF estimate of 12 to 46% ([@B13], [@B21]), we found that 3 to 11 of the 23 OPC in both sexes were attributable to HPV infection. The combined ASR for OPC attributable to HPV infection ranged from 0.1 to 0.4 per 100,000; 0.1 to 0.4 per 100,000 for males and 0.0 to 0.3 per 100,000 for females (Table [4](#T4){ref-type="table"}).

Penile Cancer and HPV {#S3-7}
---------------------

Two cases of penile cancers were reported by the registries. Of these two cases, one penile cancer case was attributable to HPV infection using a PAF of 48% ([@B13], [@B23]). The ASR for penile cancer attributable to HPV was 0.1 per 100,000 (Table [4](#T4){ref-type="table"}).

Bladder Cancer and Schistosoma {#S3-8}
------------------------------

The two registries reported 44 cases of bladder cancers in the study period. More cases were reported in males (30 cases) compared to females (14 cases). The combined ASR was 1.3 per 100,000, with ASR of 1.4 per 100,000 and 1.1 per 100,000 in males and females, respectively. Using a PAF estimate of 56% ([@B13]), we estimated that 25 bladder cancer cases were attributable to Schistosoma infection, with combined ASR of 0.7 per 100,000; 0.8 per 100,000 in men and 0.6 per 100,000 in women (Table [4](#T4){ref-type="table"}).

Liver Cancer and HBV/HCV {#S3-9}
------------------------

A total of 145 liver cancer cases were reported in both sexes from 2012 to 2014 by ABCR and ECR. Of these, 52 cases occurred in females and 93 cases were seen in males (Table [3](#T3){ref-type="table"}). Liver cancer was the most common infections-associated cancer in males, representing 11.9% of male cancers. In females, liver cancer was the second most common infections-associated cancer constituting 3.9% of all female cancers reported by the PBCRs. The combined ASR for liver cancer was 3.4 per 100,000, with 4.0 per 100,000 in males and 2.7 per 100,000 in females, respectively (Table [3](#T3){ref-type="table"}). Liver cancer was most commonly seen in the 25 to 34 and 35 to 44 years age groups with 37 cases, each in females. In males, liver cancer cases were commoner among the 25 to 34 years age group with 23 cases. Using the PAF estimate of 92% ([@B13]), we estimated that 134 cases of the 145 liver cancer cases reported were attributable to HBV/HCV infection with combined ASR of 3.1 per 100,000; 2.5 per 100,000 in males and 3.7 per 100,000 in females (Table [4](#T4){ref-type="table"}).

Stomach Cancer and *Helicobacter pylori* {#S3-10}
----------------------------------------

There were 56 cases of stomach cancers reported in our study with 23 cases in females and 33 cases in males (Table [3](#T3){ref-type="table"}). Stomach cancer accounted for 1.7% of all female cancers and 4.4% of all male cancers reported by the ABCR and ECR from 2012 to 2014 (Table [3](#T3){ref-type="table"}). The combined ASR was 1.6 per 100,000, with 1.4 per 100,000 in females and 1.7 per 100,000 in males. Stomach cancer was more common among the 45 to 54 years age groups in both sexes, with 13 cases in females and 11 cases in males. Using a PAF estimate of 74% ([@B13]), we estimated that 41 cases of the 56 cases of stomach cancer were attributable to *H. pylori* infection, with combined ASR of 1.1 per 100,000; 1.2 per 100,000 in males and 1.0 per 100,000 in females (Table [4](#T4){ref-type="table"}).

Nasopharyngeal Cancer and EBV {#S3-11}
-----------------------------

The PBCRs reported 81 nasopharyngeal cancer cases in both sexes from 2012 to 2014. Thirty-four cancer cases were seen in females, representing 2.5% of female cancers and 47 cancer cases in males, constituting 6.1% of male cancers (Table [3](#T3){ref-type="table"}). The combined ASR was 1.6 per 100,000, with 1.5 per 100,000 in females and 1.7 per 100,000 in males. Nasopharyngeal cancer was more common in males in the 45 to 54 years age group with 18 cases, while in females, it was most common among the 45 to 54 and 55 to 64 years age groups with 13 and 14 cases, respectively. We used a PAF estimate of 100% because EBV has been shown to be a necessary cause of nasopharyngeal cancer ([@B13], [@B28]) and assumed that all 81 nasopharyngeal cancers were attributable to EBV infection (Table [3](#T3){ref-type="table"}). The combined ASR for nasopharyngeal cancers attributable to EBV infection was 1.6 per 100,000; 1.7 per 100,000 in males and 1.5 per 100,000 females (Table [4](#T4){ref-type="table"}).

Hodgkin Lymphoma and EBV {#S3-12}
------------------------

Some 45 HL cases were reported by ABCR and ECR within the study period. Of these, 17 cases occurred in females and 28 cases in males (Table [3](#T3){ref-type="table"}). The combined ASR was 0.8 per 100,000, with 0.5 per 100,000 in females and 1.0 per 100,000 in males. The highest numbers of HL cases were reported in the 25 to 34 years age groups in both sexes with 13 cases. In our study, we calculated the EBV-attributable fraction for HL using a PAF estimate of 80% from a study by Lynnette et al. and a meta-analysis ([@B29], [@B30]). Thirty-six of the 45 HL cases reported by the PBCRs were attributable to EBV. The combined ASR for HL attributable to EBV infection was 1.0 per 100,000; 0.4 per 100,000 in females and 1.4 per 100,000 in males (Table [4](#T4){ref-type="table"}).

Non-Hodgkin Lymphoma and EBV/HIV {#S3-13}
--------------------------------

The registries reported 110 cases of NHL from 2012 to 2014. Forty-nine cases were seen in females and 61 cases in males (Table [3](#T3){ref-type="table"}). NHL was the second most common infection-associated cancer reported in males. The combined ASR was 5.0 per 100,000, with 2.3 per 100,000 in females and 2.7 per 100,000 in males. We used a PAF of 100% as sero-epidemiological studies have shown a strong association of NHL with EBV ([@B13]). We estimated that 110 cases reported by the registries were attributable to EBV and HIV, with combined ASR of 2.5 per 100,000; 2.3 per 100,000 in females and 2.7 per 100,000 in males (Table [4](#T4){ref-type="table"}).

Kaposi Sarcoma and HIV/HHV8 {#S3-14}
---------------------------

The combined ASR for KS reported by the PBCR was 2.4 per 100,000, with 1.1 per 100,000 in males and 1.3 per 100,000 in females (Table [3](#T3){ref-type="table"}). There were 61 cases reported from 2012 to 2014. Of these, 26 cases occurred in females representing 2.0% of all female cancers, while 28 cases were seen in males accounting for 4.6% of all male cancers (Table [3](#T3){ref-type="table"}). We found the highest number of KS cases in both sexes in the 35 to 44 years and 45 to 54 years age groups with 24 cases each. We used a PAF estimate of 100% in our study because studies have shown that HHV8 and KS in HIV positive individuals is an AIDS defining cancer ([@B32], [@B36]). Therefore, we assume that all 61 cases of KS reported by the PBCRs in 2012--2014 were attributable to HIV/HHV8 infection with combined ASR of 1.2 per 100,000, with 1.1 per 100,000 in males and 1.3 per 100,000 in females (Table [4](#T4){ref-type="table"}).

Discussion {#S4}
==========

In this study, we found that almost a quarter of cancer cases (23.8%) in these two PBCR were associated with infections and most of these (22.0% of new cancer cases and 92% of the infections-associated cancers) were indeed attributable to infections. This is similar to estimates of 22.9% for other developing countries; higher than 7.4% estimated for developed countries and expectedly higher than global average of 16.1% reported by de Martel et al in 2008 ([@B1]).

Human papillomavirus infection is one of the most important infections-associated with cancers worldwide ([@B37]). In 2008, 700,000 of the 2 million cases of infections-associated cancers occurred at sites, such as cervix uteri, anus, penis, vulva, vagina, and oropharynx where HPV infections are prevalent. Some 610,000 of these cancers were attributable to HPV infection and 490,000 (80.4%) were estimated to have occurred in developing countries ([@B37]). HPV-associated cancers were the commonest infections-associated cancer in this study. This contrasts with the situation in more developed regions of the world and Northeast Asia where *H. pylori* infection is the most common infections-associated with cancers ([@B1], [@B7]).

Cervical cancer was the most common infections-associated cancer in this study and is the second commonest cancer in Nigerian women ([@B10]). The ASR for cervical cancer in this study was 28.3 per 100,000 and that is similar to estimates for West-Africa (ASR of 29.3 per 100,000) ([@B38]) and SSA that ranges from 20 to 35 per 100,000 ([@B11]). Early detection measures are particularly relevant for cervical cancer and population-wide screening programs if implemented alongside vaccination with HPV would significantly reduce incidence and mortality from cervical cancer and other HPV-associated cancers in Nigeria.

*Helicobacter pylori* infection is associated with stomach cancers but these are relatively rare in the Nigerian population. The prevalence of stomach cancers in SSA is low with the lowest incidence rates reported in Western Africa ([@B39]), somewhat higher rates in Eastern Africa ([@B40]) while the highest rates globally are seen in Eastern Asia ([@B41]). However, given that patients with dyspeptic symptoms suspicious of stomach cancer may not be adequately investigated due to paucity of endoscopy and biopsy services in this environment, the incidence of stomach cancers may be under-reported ([@B42]).

In our study, liver cancer was the most common infections-associated cancer in males. Over 75% of liver cancers are hepatocellular carcinomas (HCC) that are largely due to infection with HBV and HCV ([@B43]), which are endemic in SSA ([@B44], [@B45]). There is wide variation in liver cancer incidence rates worldwide due to geographic variation in prevalence of chronic HBV and HCV infections ([@B43]), aflatoxin exposure ([@B46]), alcohol-related cirrhosis ([@B47]), fatty liver disease ([@B48]), obesity, and smoking ([@B43]). In our study, we found ASR of 4.0 per 100,000 in males and 1.1 per 100,000 in females with a rate ratio of 3.6, similar to findings from The Gambia of 1.6 per 100,000 in 2009 ([@B49]). Somewhat higher incidence rates have been reported from Zimbabwe, 14.4 per 100,000 and 12.7 per 100,000 in males and females, respectively (rate ratio 1.1) and in Uganda 8.7 per 100,000 and 5.8 per 100,000 in males and females respectively (rate ratio 1.5) ([@B43]). The highest liver cancer incidence rates worldwide were reported in Eastern Asia although these rates appear to be declining in three of the seven countries included in the study namely China, the Philippines, and Japan ([@B43]).

Human papillomavirus ([@B50]) was the first virus shown to be associated with human cancer and is linked with several cancers, including nasopharyngeal cancers, HL, and NHL ([@B13]). In our study, the ASR of nasopharyngeal cancers was 1.7 per 100,000 in males and 1.5 per 100,000 in females. Although nasopharyngeal cancers are rare in many populations, high incidence rates have been reported in Northern Africa ([@B51]). Other risk factors for nasopharyngeal cancers include consumption of salt-preserved fish, positive family history, tobacco smoking, and a history of chronic respiratory tract conditions ([@B52]). Protective factors include consumption of fruits and vegetables and possession of some human leukocyte antigen (HLA) genotypes that may reduce risk ([@B53]). NHL is an AIDS defining cancer. However, the availability of antiretroviral therapy has largely led to a reduction in the risk of NHL in HIV-infected individuals in recent times ([@B31]).

The increasing availability of antiretroviral therapy has contributed to the reduction in the incidence of KS among HIV positive individuals in developing countries. KS is an AIDS defining cancer that is linked to HIV and HHV8 infections ([@B53]). Evidence of a strong association exists between KS and immunocompromised individuals because KS risk increases as immune function is impaired in HIV-infected individuals ([@B54]). The prevalence of HHV8 is higher in HIV-infected men who have sex with men (MSM) than in heterosexual HIV-infected individuals ([@B53]). The incidence rates of KS in our study were 1.1 in males and 1.3 in females per 100,000. These low rates were similar to findings by Bah et al. in The Gambia ([@B55]), and significantly lower than incidence rates reported from Zimbabwe 47.2 per 100,000 and Uganda 39.3 per 100,000 ([@B55]).

Our study has several important limitations. We used cancer registry data from two PBCRs in Nigeria because the two other PBCR have just been established and did not have data covering the same period. While we strive to ensure high quality of cancer registration in Nigeria, our data may be incomplete given the high proportion of morphologically verified cases in the databases of the registries that we used. There may be under-reporting of cancers that are hard to biopsy because of limited diagnostic facilities, and cost of diagnosis and treatment. Another limitation is the small sample sizes of the few prevalence studies of infectious agents in Nigeria, which necessitated the use of data from meta-analyses to estimate our PAF. These estimates may not be a true representation of the Nigerian population. We did not estimate the incidence of certain cancers, such as acute T-cell leukemia/lymphoma which is associated with HTLV-1 or bile duct cancer which is associated with *C. sinensis* and *O. viverrini* because few of these cancers were reported by the registries.

In our sensitivity analyses, we found that 35.9% of the Nigerian cancer cases reported in GLOBOCAN 2012 database were associated with infections and 33.8% were attributable to infections. The differences in proportion of cancers attributable to infections from our PBCRs and GLOBOCAN 2012 data for Nigeria could be due to the fact that the GLOBOCAN 2012 database contained incidence estimates for only 7 out of the 12 infections-associated cancers that we considered. Our findings also shows that liver cancer was either over-estimated in GLOBOCAN 2012 or under-reported by the PBCRs whose data we analyzed in this study. GLOBOCAN 2012 reported ASR of 7.5 per 100 000 for liver cancer in females and 13.8 per 100,000 in males, while we found ASR of 2.5 per 100,000 in females and 3.7 per 100,000 in males.

Conclusion {#S5}
==========

Despite these limitations, our study confirms the crucial role that infections plays in the etiology of a wide range of cancers in the Nigerian population and the opportunities for reducing morbidity and mortality through control of these infections. Prophylactic vaccination against HPV and HBV, and effective management of *H. pylori* and HCV infections offer tremendous opportunities to significantly reduce the burden of infections-attributable cancers in Nigeria.
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